

Company

Dallah Healthcare Co.
1Q26 Result Review

Rating

Under Review

Bloomberg Ticker

DALLAH AB

Date

17 May 2026

Results

Target Price (SAR) Under Review


Total Return -

Current Market Price (SAR)	113.2
52wk High / Low (SAR)	157.3/90
12m Average Vol. (m)	92.1
Mkt. Cap. (USD/SAR bn)	3.1/11.5
Shares Outstanding (mn)	101.6
Free Float (%)	48.0%
3M ADTV (SAR mn)	18.8
6M ADTV (SAR mn)	13.6
P/E'26e (x)	28.0
P/B'26e (x)	2.7
Dividend Yield '26e (%)	1.8%
Price Perf. (1m/3m) (%)	-11.4/1.2

Research Department

Email: ubhar-research@u-capital.net

For our
last report

**Revenue growth driven by acquisitions and patient volumes**

Revenue increased 22% YoY to SAR 1,013mn in 1Q26, in line with expectations, driven by higher patient visits across the Group's facilities, particularly following the consolidation of Dallah Al-Khobar Hospital and Dallah Al-Ahsa Hospital. Total patient visits increased 28% YoY to 936K, reflecting the positive contribution from recent acquisitions and continued operational growth across existing facilities.

Higher interest cost & absence of one-off gains weigh on profit

Net profit declined 46% YoY to SAR 85mn in 1Q26, primarily due to the absence of a non-recurring gain recorded in 1Q25, along with higher financing and operating costs related to acquired hospitals.

U-Capital View

Dallah Healthcare reported a YoY and QoQ decline in its net profit amid higher financing and operating cost. We are currently placing the stock under review and we will update our investment case shortly.

Financial Summary

SAR mn	1Q25	2Q25	3Q25	4Q25	1Q26	1Q26e	YoY	QoQ	Var.
P&L									
Revenue	833	1,062	1,061	1,110	1,013	1,004	22%	-9%	1%
Gross profit	298	376	381	398	334	353	12%	-16%	-5%
Operating profit	178	155	158	155	120	137	-32%	-22%	-12%
Net profit	156	124	142	117	85	103	-46%	-27%	-18%
BS									
Shareholders' Equity	4,061	4,135	4,226	4,082	4,101		1%	0%	
Ratios									
Gross profit margin	35.7%	35.4%	35.9%	35.9%	33.0%	35.1%			
Operating profit margin	21.4%	14.6%	14.8%	14.0%	11.9%	13.7%			
Net profit margin	18.7%	11.7%	13.4%	10.5%	8.3%	10.3%			
RoE (TTM)					11.3%				
P/E (TTM)					24.3				
Current P/B					2.8				

Source: Financials, TASI, Bloomberg, U Capital Research



Investment Research

Ubhar-Research@u-capital.net

Head of
Research

Tahir Abbas

+968 2494 9036 | tahir@u-capital.net

Research
Team

Rao Aamir Ali

+968 2494 9066 | rao@u-capital.net

Sandesh Shetty

+968 2494 9059 | sandesh@u-capital.net

Amira Al Alawi

+968 2494 9012 | amira.alalawi@u-capital.net

Head of
Brokerage

Talal Al Balushi

+968 2494 9051 | talal@u-capital.net

Visit us at

www.u-capital.net

Disclaimer

Recommendation

BUY

Greater than 10%

HOLD

Between
0% and +10%

SELL

Lower than 0%

Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net

PO Box 1137, PC 111, Sultanate of Oman

Tel: +968 2494 9036 | **Fax:** +968 2494 9099 | **Email:** research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.